Sigal Charles Elliott is a director of Surface Oncology, Inc.
Person profile
Roles
Address
Princeton, New Jersey
Employees
SEC CIK
Latest filings (excl ownership)
No filings
Latest ownership filings
4
ALNYLAM PHARMACEUTICALS, INC.
20 May 24
4
Surface Oncology, Inc.
8 Sep 23
4
Adaptimmune Therapeutics PLC
3 Jul 23
4
Vir Biotechnology, Inc.
24 May 23
4
ALNYLAM PHARMACEUTICALS, INC.
19 May 23
4
Vir Biotechnology, Inc.
2 Mar 23
4
Vir Biotechnology, Inc.
9 Jan 23
4
Vir Biotechnology, Inc.
5 Jan 23
4
ALNYLAM PHARMACEUTICALS, INC.
24 Aug 22
3
ALNYLAM PHARMACEUTICALS, INC.
24 Aug 22
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 May 24 | ALNY Alnylam Pharmaceuticals | Stock Option Common Stock | Grant | Acquire A | No | No | 151.22 | 5,228 | 790.58 k | 5,228 |
8 Sep 23 | SURF Surface Oncology | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 45,453 | 0.00 | 0 |
8 Sep 23 | SURF Surface Oncology | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 0.35 | 113,636 | 39.77 k | 0 |
3 Jul 23 | ADAP Adaptimmune Therapeutics | Option to purchase Ordinary Shares Ordinary Shares | Grant | Acquire A | No | No | 0.16 | 933,317 | 149.33 k | 933,317 |
22 May 23 | VIR Vir Biotechnology | Common Stock | Grant | Acquire A | No | No | 0 | 6,027 | 0.00 | 15,806 |
22 May 23 | VIR Vir Biotechnology | Stock Option Common Stock | Grant | Acquire A | No | No | 25.74 | 12,054 | 310.27 k | 12,054 |
18 May 23 | ALNY Alnylam Pharmaceuticals | Stock Option Common Stock | Grant | Acquire A | No | No | 189.87 | 3,454 | 655.81 k | 3,454 |